{"id":2839,"date":"2020-07-10T05:30:00","date_gmt":"2020-07-10T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/"},"modified":"2020-07-10T05:30:00","modified_gmt":"2020-07-10T05:30:00","slug":"i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/","title":{"rendered":"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC"},"content":{"rendered":"<p><span><span><span><strong><span><span>ANDRA KVARTALET 2020 (APRIL &#8211; JUNI)<\/span><\/span><\/strong><\/span><\/span><\/span><\/p>\n<p><span><span><strong><span>Finansiell information<\/span><\/strong><\/span><\/span><\/p>\n<ul>\n<li><span><span><span><span><span>Segment f\u00f6rs\u00e4ljning utan kapitalvaror\u00a0minskade under kvartalet med 44 procent och uppgick till 28,0 MSEK (50,5). Minskningen motsvarar 46 procent i lokala valutor. Total f\u00f6rs\u00e4ljning under kvartalet minskade med 46 procent och uppgick till 30,4 MSEK (56,4). Minskningen motsvarar 47 procent i lokala valutor.<\/span><\/span><span><span> Covid-19-pandemin har haft stor p\u00e5verkan p\u00e5 f\u00f6rs\u00e4ljning och produktmix under kvartalet. P\u00e5 de viktiga marknaderna har bolaget sett en viss \u00e5terh\u00e4mtning, i USA fr\u00e5n och med maj och i Europa fr\u00e5n och med juni.<\/span><\/span> <span><span>Nedg\u00e5ngen av lungtransplantationer har fr\u00e4mst berott p\u00e5 vilken utstr\u00e4ckning Covid-19-pandeminp\u00e5verkat intensivv\u00e5rden p\u00e5 de olika marknaderna. Eftersom transplantation \u00e4r en livsuppeh\u00e5llande behandling och transplantationer \u00e4r prioriterade av h\u00e4lsov\u00e5rdsmyndigheter v\u00e4rlden \u00f6ver \u00e4r bolagets bed\u00f6mning att den l\u00e5ngsiktiga effekten p\u00e5 efterfr\u00e5gan av transplantationspro\u00addukter kommer vara of\u00f6r\u00e4ndrad.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Varm perfusion\u00a0stod f\u00f6r 37 procent (45) av f\u00f6rs\u00e4ljningen utan kapitalvaror.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>R\u00f6relseresultatet f\u00f6re avskrivningar, EBITDA, uppgick till -5,5 MSEK (8,1) motsvarande en EBITDA-marginal om -18 procent (14). EBITDA, har under kvartalet har belastats med kostnader i samband med organisationsf\u00f6r\u00e4ndring om -4,5 MSEK. Justerat f\u00f6r detta uppg\u00e5r EBITDA f\u00f6r kvartalet till \u20131,0 MSEK (12,1), motsvarande en EBITDA-marginal om -3 procent (21). <\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>R\u00f6relseresultatet uppgick till -12,7 MSEK (1,9), efter att avskrivningar om 7,3 MSEK (6,1) belastat kvartalet. Justerat f\u00f6r ovan n\u00e4mnda kostnader uppgick r\u00f6relseresultatet till -8,2 MSEK (5,9).<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Nettoresultatet uppgick till -16,0 MSEK (2,2), vilket gav ett resultat per aktie om -0,60 SEK (0,08).<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Kassafl\u00f6de <\/span><\/span><span><span>fr\u00e5<\/span><\/span><span><span>n den l<\/span><\/span><span><span>\u00f6pande verksamheten uppgick under kvartalet till 2,4 MSEK (21,0). Kassafl\u00f6det fr\u00e5n investeringsverksamheten uppgick till -13,9 MSEK (-27,8 MSEK). <\/span><\/span><\/span><\/span><\/span><\/li>\n<\/ul>\n<p><span><strong><span>V\u00e4sentliga h\u00e4ndelser<\/span><\/strong><\/span><\/p>\n<ul>\n<li><span><span><span><span><span>Dag Andersson har utsetts till ny vd och koncernchef. XVIVO Perfusions grundare och tidigare vd, Magnus Nilsson, kvarst\u00e5r\u00a0som Senior Advisor f\u00f6r att prim\u00e4rt arbeta med R&amp;D.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Anne-Li Sigvardsson, MSc har utn\u00e4mnts till IP-chef (Chief Intellectual Property Officer). Andreas Wallinder, MD, PhD har blivit utn\u00e4mnd till Medicinsk chef (Chief Medical Officer).<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Den vetenskapliga tidskriften Nature Communications publicerade under kvartalet en artikel vilken beskriver bolagets hj\u00e4rtpreservationsteknologi och studien som visar metoden \u00e4r s\u00e4ker. <\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Universitetssjukhuset AKH i Wien, \u00d6sterrike, som \u00e4r en av de tre st\u00f6rsta lungtransplantationsklinikerna i Europa, har k\u00f6pt en XPS\u2122.<\/span><\/span><\/span><\/span><\/span><\/li>\n<\/ul>\n<p><span><span><span><strong><span><span>PERIODEN 2020 (JANUARI &#8211; JUNI)<\/span><\/span><\/strong><\/span><\/span><\/span><\/p>\n<p><span><span><strong><span>Finansiell information<\/span><\/strong><\/span><\/span><\/p>\n<ul>\n<li><span><span><span><span><span>Segment f\u00f6rs\u00e4ljning utan kapitalvaror\u00a0minskade under perioden med 26 procent och uppgick till 72,2 MSEK (97,3). Minskningen motsvarar 28 procent i lokala valutor. Total f\u00f6rs\u00e4ljning (inklusive kapitalvaror) under perioden minskade med 26 procent och uppgick till 76,9 MSEK (104,1). Minskningen motsvarar 28 procent i lokala valutor.<\/span><\/span><span><span> Covid-19-pandemin har haft stor p\u00e5verkan p\u00e5 f\u00f6rs\u00e4ljning och produktmix under perioden.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Varm perfusion\u00a0stod f\u00f6r 31 procent (44) av f\u00f6rs\u00e4ljningen utan kapitalvaror.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>R\u00f6relseresultatet f\u00f6re avskrivningar, EBITDA ,uppgick till 2,1 MSEK (11,3) motsvarande en EBITDA-marginal om 3 procent (11). EBITDA, har belastats med kostnader i samband med organisationsf\u00f6r\u00e4ndringar med -4,5 MSEK, medan uppl\u00f6sning av kostnadsreserveringar f\u00f6r aktiebaserade bonusprogram f\u00f6r anst\u00e4llda utanf\u00f6r Sverige bidragit positivt med 2,5 MSEK. Justerat f\u00f6r dessa poster uppg\u00e5r EBITDA f\u00f6r perioden till 4,1 MSEK (20,8), motsvarande en EBITDA-marginal om 5 procent (20). <\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>R\u00f6relseresultatet uppgick till -12,7 MSEK (0,1), efter att avskrivningar om 14,8 MSEK (11,2) belastat perioden. Justerat f\u00f6r ovan n\u00e4mnda poster uppgick r\u00f6relseresultatet till -10,7 MSEK (9,6).<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Nettoresultatet uppgick till -9,5 MSEK (1,9), vilket gav ett resultat per aktie om -0,36 SEK (0,07).<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>Kassafl\u00f6de<\/span><\/span><span><span> fr\u00e5<\/span><\/span><span><span>n den l<\/span><\/span><span><span>\u00f6pande verksamheten uppgick under perioden till 11,6 MSEK (22,1). Kassafl\u00f6det fr\u00e5n investeringsverksamheten uppgick till -29,7 MSEK (-39,5 MSEK).<\/span><\/span><\/span><\/span><\/span><\/li>\n<\/ul>\n<p><span><strong><span>V\u00e4sentliga h\u00e4ndelser <\/span><\/strong><\/span><\/p>\n<ul>\n<li><span><span><span><span><span>Den vidareutvecklade och mer anv\u00e4ndarv\u00e4nliga Perfadex<sup>\u00ae<\/sup> Plus med Click Port har lanserats i hela v\u00e4rlden.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span><span>En XPS\u2122 har f\u00f6r f\u00f6rsta g\u00e5ngen levererats till ett pediatriskt (barn) sjukhus i Rom, Italien. Vid periodens utg\u00e5ng hade 53 kliniker tillg\u00e5ng till XPS\u2122 eller LS\u2122.<\/span><\/span><\/span><\/span><\/span><\/li>\n<li><span><span><span><span>Bolagets studier f\u00f6r PrimECC<sup>\u00ae<\/sup> och hj\u00e4rtpreservation inf\u00f6r transplantation i Europa \u00e4r klara f\u00f6r att inkludera de f\u00f6rsta patienterna. Dessa tv\u00e5 studier har inte kunnat starta under perioden p\u00e5 grund av att kliniker i Europa tillf\u00e4lligt pausat alla kliniska studier under Covid-19-pandemin.<\/span><\/span><\/span><\/span><\/li>\n<\/ul>\n<p><span><span><strong><span><span>TELEFONKONFERENS<\/span><\/span><\/strong><\/span><\/span><\/p>\n<p><span><span><span><span><span><span><span>VD Dag Andersson presenterar rapporten vid en telefonkonferens klockan 14.00 fredagen den 10 juli 2020. Telefon: +46 (0)8 5664 2651, ange kod 84626045#.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/span><\/p>\n<p><span><span>Christoffer Rosenblad, CFO, +46 735-192159, christoffer.rosenblad@xvivoperfusion.com<br \/>\nDag Andersson, VD, +46 31-788 21 50, dag.andersson@xvivoperfusion.com<\/span><\/span><\/p>\n<p><span><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/span><\/p>\n<p><span><span>Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning och lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 07:30 den 10\u00a0juli 2020.<\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ANDRA KVARTALET 2020 (APRIL &#8211; JUNI) Finansiell information Segment f\u00f6rs\u00e4ljning utan kapitalvaror\u00a0minskade under kvartalet med 44 procent och uppgick till&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2839","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO\" \/>\n<meta property=\"og:description\" content=\"ANDRA KVARTALET 2020 (APRIL &#8211; JUNI) Finansiell information Segment f\u00f6rs\u00e4ljning utan kapitalvaror\u00a0minskade under kvartalet med 44 procent och uppgick till...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\\\/\",\"name\":\"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-07-10T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/","og_locale":"en_US","og_type":"article","og_title":"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO","og_description":"ANDRA KVARTALET 2020 (APRIL &#8211; JUNI) Finansiell information Segment f\u00f6rs\u00e4ljning utan kapitalvaror\u00a0minskade under kvartalet med 44 procent och uppgick till...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/","name":"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-07-10T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/i-startblocken-infor-studieuppstart-for-hjartpreservation-och-primecc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"I startblocken inf\u00f6r studieuppstart f\u00f6r hj\u00e4rtpreservation och PrimECC"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}